drugset

drugset / Trial / NCT02953665

Safety and Efficacy of Liraglutide in Parkinson's Disease

NCT02953665 ↗

Phase 2 Completed 63 enrolled Cedars-Sinai Medical Center Cure Parkinson's · collab Novo Nordisk A/S · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).

Timeline

Start: 2017-04-03
Primary completion: 2022-08-03
Completion: 2022-08-03

Publications

Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, Holscher C. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease. J Parkinsons Dis. 2020;10(2):523-542. doi: 10.3233/JPD-191768.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Liraglutide	Peptide	1.2 mg	Subcutaneous
Comparator	Liraglutide	Peptide	1.8 mg	Subcutaneous

Indications